Long-Term Thesis
Figures converted from CNY (¥) and HKD (HK$) at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Long-Term Thesis — 5-to-10-Year Underwriting View
1. Long-Term Thesis in One Page
The long-term thesis is that Horizon becomes the Mobileye of China — at four times Mobileye's growth rate, with a 92%-gross-margin software-attach engine Mobileye does not have — converting today's 47.7% domestic ADAS share, 290+ designed-in vehicle models, and 10M+ cumulative Journey installed base into a recurring, software-led automotive AI platform by the early 2030s. The 5-to-10-year case works only if three things happen in sequence: (a) Journey 6/7 unit shipments scale through a doubling China L2+ penetration market (24% in 2025 to 52% by 2030 per Qualcomm), (b) R&D-to-revenue compresses from 137% today through Mobileye's 60% by FY2028 to a mature sub-30% by FY2030, and (c) the CARIZON/VW lock-in becomes the bridgehead to a global non-Chinese OEM revenue line. This is not a long-duration compounder unless OEM in-housing stays contained — BYD's DiPilot, NIO's Shenji, and the Zeekr-at-Mobileye precedent are the documented mechanism by which the design-win-for-life moat becomes a transit corridor. The durable thesis variable is whether the independent-merchant lane stays structurally defended by Chinese OEMs' revealed preference against Huawei dependence and against captive-silicon dependence on rivals, or whether the mass-market 44.2% NOA share gets repriced as a temporary cycle position. At 14× FY2025 sales the market is paying for a Mobileye destination with a Chinese-policy premium; the question over the next five years is whether the destination justifies the premium and whether Horizon arrives before equity dilution and Huawei share gains have eroded the option value.
The single most important long-term conclusion. Horizon is being underwritten as a China policy-protected merchant that converges to Mobileye-shape economics on a 4× Mobileye growth rate. The thesis is real but narrow: it depends on the independent-merchant lane staying defended by Chinese OEMs' refusal to depend on Huawei or on rival captive silicon, and on R&D operating leverage arriving inside the next four reporting years. Each of those two things has been broadly true so far. Neither is guaranteed.
2. The 5-to-10-Year Underwriting Map
The driver that matters most is #2 — R&D operating leverage arriving. Drivers #1, #5, and #6 describe market backdrops; #3 and #4 describe distribution moats; but #2 is the single financial mechanism that turns Horizon from a China champion at 25× P/S into a defensible business that earns money. It is also the one driver where the most recent data point (H1 2025, R&D-to-revenue stepped up to 147% from 132%) went the wrong way. Without driver #2 materialising over the next four reporting years, every other driver is just a story.
3. Compounding Path
The model is built on three multiplicative levers, each independently observable and each with a quantified destination in either management guidance or a peer-comp anchor. Annual figures below combine reported FY2021–FY2024, FY2025 actuals (revenue $537M reported March 2026), and a base-case 5-to-10-year frame anchored to the raised 60% three-year CAGR guide and the Mobileye margin destination.
The compounding mechanics. Growth — base case anchors to management's raised 60% CAGR guide for FY2026-28 ($537M compounding to roughly $2.1B), then decelerates to a Mobileye-shape mid-teens by FY2030 as the China L2+ pool saturates and the third Journey generation enters the curve. Gross margin — drifts from 77% (FY24 peak, license-heavy) through a mid-60s trough during the silicon ramp (FY25-26) before stabilising near 62-64% as hardware mix climbs toward 60% and the high-tier J6/J7 SKU mix carries chip GM toward Mobileye's 47.7%. Cash conversion — operating cash flow already crossed zero in FY24 ($+2.4M); capex stays elevated at $115M-$175M/year through Journey 7 tape-out (FY25-26) before normalising; free cash flow turns positive around FY28. Reinvestment — R&D is the dominant call on capital and the path is the entire equity thesis: 137% (FY25) to 95% (FY26E) to 70% (FY27E) to 55% (FY28E, Mobileye-level), achieved by holding R&D growth at roughly half of revenue growth for four consecutive years. Balance sheet — $2.1B cash + the two 2025 top-up placements ($1.4B combined) plus the runway from interest income means no further capital is needed to fund the path if operating losses narrow on the FY2027 schedule. The single load-bearing assumption is R&D leverage — every line of the compounding table compounds off it.
The base-case math is not bull-case math. The $1.48 sell-side mean target prices in something closer to $2.1B FY2028 revenue with $440-585M operating profit — that requires 60% growth holding through FY28 and gross margin recovering toward 70%. The frame above is the underwriteable base case: 50-55% growth holding, gross margin stabilising mid-60s, breakeven slipping into FY2028 rather than FY2027. The difference between the two paths is one Journey-7 design-win wave and one half of license/services re-acceleration.
4. Durability and Moat Tests
Tests #1 and #2 are the load-bearing ones — the first competitive (will OEM in-housing eat the design-win base) and the second financial (does hardware GM walk toward Mobileye's mature level). Both have current evidence that is directionally favourable but recently mixed: no top-10 OEM has defected yet, but BYD's DiPilot expansion narrows the addressable base inside the company's own customer set; hardware GM rose 170bps in the FY2024 ramp, but H1 2025 stepped R&D-to-revenue back up to 147% from 132%. The next four reporting cycles, not the next one, will decide the multi-year thesis.
5. Management and Capital Allocation Over a Cycle
Founder Dr. Kai Yu has held the CEO seat since the 2015 spin-out from Baidu's Institute of Deep Learning. The first credibility test of the public era — five of six concrete promises kept (10M cumulative Journey shipments, HSD Q3 2025 mass production with Chery, 4M+ FY2025 unit shipments, license-and-services scaling, related-party transaction caps observed to the dollar) — is the right kind of evidence for a long-duration thesis. The single missed promise (CARIZON ramp tracking lower losses than the actual -$76M FY24 and ~-$112M annualised H1 2025) was disclosed flatly rather than reframed.
The longer-cycle test is capital allocation. The first 18 months as a public company chose equity dilution over operating discipline as the funding model: two top-up placements in 2025 ($597M in June, $812M in September) added roughly 8% net dilution at discount-to-spot prices, on top of the IPO $690M raise. The April 2026 buyback authorisation of up to 10% of shares (1.32B against 13.2B outstanding) is unused as of the reference date — capital return capacity exists but the realised pattern is "issue, do not return." Founder economic stake is 13.7% against 53.6% of votes through the weighted-voting structure, which means there is no governance lever to force capital discipline if the realised pattern continues — minority shareholders cannot win a contested vote on anything outside the Reserved Matters list.
What looks right over a 5-to-10 year horizon: the team is technically deep (CTO Dr. Chang Huang co-authored Baidu's autonomous-driving programme), customer-aligned (President Dr. Liming Chen brings 30 years of Bosch chassis-systems-China experience), and strategic shareholders (Volkswagen 15.1% capital, SAIC 7.8%) are simultaneously customers and capital providers — alignment is real where it matters for the customer franchise. Compensation is equity-loaded but performance-untethered in any explicit operating-metric sense, and three of the four independent directors joined only at the October 2024 IPO. The honest read is that the People work confirms a founder-controlled, technically credible, strategically well-connected team operating under governance that prioritises long-horizon founder vision over minority-shareholder protections. For the 5-to-10-year thesis this means: trust the operating-cadence delivery, discount the capital-allocation discipline, and watch for any sign that founder voting control gets used to push through related-party transactions outside the existing D-Robotics / CARIZON ring-fence.
The capital-allocation cadence — issue equity to fund a strategic JV that has not yet produced revenue, plus two more placements to extend runway, plus a buyback authority not yet used — is the pattern an investor must price. It is not red-flag behaviour for a pre-breakeven semiconductor company; it is the textbook funding model. But every $1 of additional dilution before FY2027 breakeven raises the bar on the eventual operating margin and revenue scale required to justify today's market cap.
6. Failure Modes
The single most dangerous failure mode is #1 — OEM in-housing acceleration — because it has a documented industry precedent (Mobileye losing Zeekr Q3 2024), an early stage of revealed activity (BYD DiPilot, NIO Shenji), and the multi-year unit-shipment trajectory that 25× P/S is paying for collapses on a single top-10 defection. The second most dangerous is #2 — R&D leverage failing to arrive — because it can play out without any external trigger and the most recent print (H1 2025 R&D-to-revenue back up to 147%) already moved in that direction. Failures #3-#6 each compress the equity individually; failures #1 or #2 reset the thesis entirely.
7. What to Watch Over Years, Not Just Quarters
The long-term thesis changes most if a single top-10 China OEM publicly commits to in-house silicon for a flagship NOA program inside the 2026-2028 window — the Zeekr-at-Mobileye precedent repeating once at Horizon downgrades the switching-cost moat from "narrow" to "moat not proven," resets the multi-year revenue CAGR the market is paying for, and forces the multiple to anchor on Mobileye's 3.4× EV/Sales rather than today's 14×.